Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced that the Food and Drug Administration granted breakthrough therapy designation to its investigational drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE